Dominantly inherited micro-satellite instable cancer – the four Lynch syndromes - an EHTG, PLSD position statement

[1]  Aung Ko Win,et al.  Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database , 2023, EClinicalMedicine.

[2]  P. Peltomäki,et al.  Lynch syndrome genetics and clinical implications. , 2023, Gastroenterology.

[3]  Charles J. Kahi,et al.  Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  L. Guerrini-Rousseau,et al.  Constitutional microsatellite instability, genotype, and phenotype correlations in Constitutional Mismatch Repair Deficiency. , 2022, Gastroenterology.

[5]  P. Møller.  The Prospective Lynch Syndrome Database: background, design, main results and complete MySQL code , 2022, Hereditary Cancer in Clinical Practice.

[6]  M. Kloor,et al.  Is HLA type a possible cancer risk modifier in Lynch syndrome? , 2022, International journal of cancer.

[7]  L. Cabezón-Gutiérrez,et al.  Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach? , 2022, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  Aung Ko Win,et al.  Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium , 2022, Hereditary Cancer in Clinical Practice.

[9]  B. Kramer,et al.  Cancer overdiagnosis: A challenge in the era of screening , 2022, Journal of the National Cancer Center.

[10]  D. Bishop,et al.  Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up , 2022, Cancer prevention research.

[11]  K. Takehara,et al.  Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma , 2022, Journal of gynecologic oncology.

[12]  T. André,et al.  Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[13]  Lurdes Y. T. Inoue,et al.  Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort , 2022, Annals of Internal Medicine.

[14]  P. Bork,et al.  Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model. , 2021, Gastroenterology.

[15]  Katherine M. Tucker,et al.  Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. , 2021, The Lancet. Oncology.

[16]  Aung Ko Win,et al.  Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report , 2020, Genetics in Medicine.

[17]  Vincent Heuveline,et al.  Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure , 2020, bioRxiv.

[18]  M. Kloor,et al.  The “unnatural” history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance , 2020, International journal of cancer.

[19]  M. Kloor,et al.  A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial , 2020, Clinical Cancer Research.

[20]  D. Bishop,et al.  Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial , 2020, The Lancet.

[21]  P. Møller.  The Prospective Lynch Syndrome Database reports enable evidence-based personal precision health care , 2020, Hereditary Cancer in Clinical Practice.

[22]  M. Kloor,et al.  Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report , 2019, Hereditary Cancer in Clinical Practice.

[23]  M. Kloor,et al.  Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report , 2019, Hereditary Cancer in Clinical Practice.

[24]  M. Kloor,et al.  No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. , 2018, Gastroenterology.

[25]  Surajit Sinha,et al.  The impact of microsatellite stability status in colorectal cancer. , 2018, Current problems in cancer.

[26]  M. Kloor,et al.  Three molecular pathways model colorectal carcinogenesis in Lynch syndrome , 2018, International journal of cancer.

[27]  P. Møller,et al.  Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report , 2017, Hereditary Cancer in Clinical Practice.

[28]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[29]  P. Møller,et al.  Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database , 2016, Gut.

[30]  M. Kloor,et al.  CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome , 2016, Familial Cancer.

[31]  M. Kloor,et al.  CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome , 2016, Familial Cancer.

[32]  P. Devilee,et al.  Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers , 2015, European Journal of Human Genetics.

[33]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[34]  Kristopher L. Nazor,et al.  Epigenetic Regulation of Pluripotency and Differentiation , 2014, Circulation research.

[35]  B. Karlan,et al.  Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Møller,et al.  Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers , 2013, International journal of cancer.

[37]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[38]  R. Kuiper,et al.  EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients , 2012, Familial Cancer.

[39]  Axel Benner,et al.  Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. , 2012, The Lancet. Oncology.

[40]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[41]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[42]  P. Møller,et al.  Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers , 2010, Journal of Medical Genetics.

[43]  P. Møller,et al.  Recommendations to improve identification of hereditary and familial colorectal cancer in Europe , 2010, Familial Cancer.

[44]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  V. Torri,et al.  Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer , 2007, Clinical Cancer Research.

[46]  Eero Pukkala,et al.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. , 2005, Gastroenterology.

[47]  J. Jass.  Limitations of the Adenoma–Carcinoma Sequence in Colorectum , 2004, Clinical Cancer Research.

[48]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[49]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[50]  P. Sistonen,et al.  Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. , 1995, Gastroenterology.

[51]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[52]  J. Mecklin,et al.  Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. , 1986, Gastroenterology.

[53]  K. Wimmer,et al.  Constitutional Mismatch Repair Deficiency , 2018 .

[54]  P. Møller,et al.  The Prospective Lynch Syndrome Database , 2018 .

[55]  Sigve Nakken,et al.  Databases: Intentions, Capabilities, and Limitations , 2018 .

[56]  J. Stockman.  Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome , 2013 .

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..